ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "d361a361-a115-473f-a8eb-48a6513f7b70"}, "_deposit": {"id": "3770", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3770"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003770", "sets": ["462"]}, "author_link": ["6933", "6934", "6935", "6936", "6937", "6938", "6939", "6940", "6941", "6942"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "530", "bibliographicPageStart": "524", "bibliographicVolumeNumber": "18", "bibliographic_titles": [{"bibliographic_title": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):524-530 (2013)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Ishizuka, Osamu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.gmfaHekh.html"}, {"subitem_link_text": "Nishizawa, Osamu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WeyeWmyU.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000320456500025"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "SPRINGER JAPAN KK"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22552359"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/22552359", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s10147-012-0413-9"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s10147-012-0413-9", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11086579", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Prostate cancer; Androgen deprivation therapy; Luteinizing hormone-releasing hormone agonist"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "SERUM TESTOSTERONE; CARCINOMA; CASTRATION; GOSERELIN; ESTROGEN; ACETATE; FAILURE"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide."}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ishizuka,  Osamu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6933", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa,  Osamu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6934", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa,  Shuji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6935", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Satoh,  Tomoya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6936", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wajiki,  Masahisa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6937", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kiyokawa,  Hideo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6938", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue,  Yoshihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6939", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi,  Shinya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6940", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizusawa,  Hiroya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6941", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakagawa,  Tatsuo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6942", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf", "filesize": [{"value": "192.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 192300.0, "url": {"label": "Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3770/files/Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf"}, "version_id": "58a1d3a0-b419-4806-a873-52b593fe4c00"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Androgen deprivation therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Luteinizing hormone-releasing hormone agonist", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["462"], "permalink_uri": "http://hdl.handle.net/10091/17334", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2014-01-21"}, "publish_date": "2014-01-21", "publish_status": "0", "recid": "3770", "relation": {}, "relation_version_is_last": true, "title": ["Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer"], "weko_shared_id": -1}
  1. 050 医学部, 大学院医学系研究科
  2. 0501 学術論文

Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer

http://hdl.handle.net/10091/17334
http://hdl.handle.net/10091/17334
209ce535-8152-45d0-8bcc-6c17bcf0a64c
名前 / ファイル ライセンス アクション
Comparison_efficacy_safety_1-and Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf (192.3 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2014-01-21
タイトル
言語 en
タイトル Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer
言語
言語 eng
キーワード
主題Scheme Other
主題 Prostate cancer
キーワード
主題Scheme Other
主題 Androgen deprivation therapy
キーワード
主題Scheme Other
主題 Luteinizing hormone-releasing hormone agonist
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Ishizuka, Osamu

× Ishizuka, Osamu

WEKO 6933

en Ishizuka, Osamu

Search repository
Nishizawa, Osamu

× Nishizawa, Osamu

WEKO 6934

en Nishizawa, Osamu

Search repository
Nishizawa, Shuji

× Nishizawa, Shuji

WEKO 6935

en Nishizawa, Shuji

Search repository
Satoh, Tomoya

× Satoh, Tomoya

WEKO 6936

en Satoh, Tomoya

Search repository
Wajiki, Masahisa

× Wajiki, Masahisa

WEKO 6937

en Wajiki, Masahisa

Search repository
Kiyokawa, Hideo

× Kiyokawa, Hideo

WEKO 6938

en Kiyokawa, Hideo

Search repository
Inoue, Yoshihiro

× Inoue, Yoshihiro

WEKO 6939

en Inoue, Yoshihiro

Search repository
Kobayashi, Shinya

× Kobayashi, Shinya

WEKO 6940

en Kobayashi, Shinya

Search repository
Mizusawa, Hiroya

× Mizusawa, Hiroya

WEKO 6941

en Mizusawa, Hiroya

Search repository
Nakagawa, Tatsuo

× Nakagawa, Tatsuo

WEKO 6942

en Nakagawa, Tatsuo

Search repository
信州大学研究者総覧へのリンク
氏名 Ishizuka, Osamu
URL http://soar-rd.shinshu-u.ac.jp/profile/ja.gmfaHekh.html
信州大学研究者総覧へのリンク
氏名 Nishizawa, Osamu
URL http://soar-rd.shinshu-u.ac.jp/profile/ja.WeyeWmyU.html
出版者
出版者 SPRINGER JAPAN KK
引用
内容記述タイプ Other
内容記述 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):524-530 (2013)
書誌情報 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY

巻 18, 号 3, p. 524-530, 発行日 2013-06
抄録
内容記述タイプ Abstract
内容記述 We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide.
資源タイプ(コンテンツの種類)
内容記述タイプ Other
内容記述 Article
ISSN
収録物識別子タイプ PISSN
収録物識別子 1341-9625
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA11086579
PubMed
識別子タイプ PMID
関連識別子 https://pubmed.ncbi.nlm.nih.gov/22552359
関連名称 22552359
DOI
識別子タイプ DOI
関連識別子 https://doi.org/10.1007/s10147-012-0413-9
関連名称 10.1007/s10147-012-0413-9
権利
権利情報 The original publication is available at www.springerlink.com
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
WoS
表示名 Web of Science
URL http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000320456500025
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:17:36.120309
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3